sur PREDILIFE (EPA:ALPRE)
PREDILIFE Half-Yearly Results and Outlook for 2024
On October 28, 2024, PREDILIFE published its financial results for the first half of 2024. Specializing in disease risk prediction, the company recorded stable revenues of €157,900, despite an uncertain economic context. Strategic partnerships, particularly with recognized brokers such as Diot Siaci and Mercer, have strengthened its position in the market for predictive assessments for employees.
Furthermore, the company continues its investments in MammoRisk®, with the MyPebs clinical trial. External evaluations have estimated the potential value of this activity at €207.3 million.
Stéphane Ragusa, CEO, expresses his confidence in the expected growth in turnover for 2024, affirming the efficiency and growing potential of the offer.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de PREDILIFE